Catalent Inc/ US1488061029 /
2024-11-07 10:10:00 PM | Chg. -0.03 | Volume | Bid2:00:00 AM | Ask2:00:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
59.92USD | -0.05% | 2.19 mill. Turnover: 82.94 mill. |
59.25Bid Size: 100 | 60.57Ask Size: 100 | 10.88 bill.USD | - | - |
GlobeNewswire
05-28
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
05-17
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
05-14
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
05-08
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cance...
GlobeNewswire
04-26
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – CTLT, MGRC, CHRD, HRT
GlobeNewswire
04-11
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
04-04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire
03-01
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
03-01
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
02-28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...